Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial.
about
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersIndividual differences in recovery from traumatic fearAn Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical TrialsSleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory.Can fear extinction be enhanced? A review of pharmacological and behavioral findings.Combining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke.On the resilience of remote traumatic memories against exposure therapy-mediated attenuation.A role beyond learning for NMDA receptors in reward-based decision-making-a pharmacological study using d-cycloserine.HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?D-cycloserine in prelimbic cortex reverses scopolamine-induced deficits in olfactory memory in rats.Looking beyond Fear and Extinction Learning: Considering Novel Treatment Targets for Anxiety.An N-methyl-D-aspartate receptor agonist facilitates sleep-independent synaptic plasticity associated with working memory capacity enhancementDeep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model.Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Sleep-dependent declarative memory consolidation--unaffected after blocking NMDA or AMPA receptors but enhanced by NMDA coagonist D-cycloserine.Recent developments in the behavioural and pharmacological enhancement of extinction of drug seeking.On the Road to Translation for PTSD Treatment: Theoretical and Practical Considerations of the Use of Human Models of Conditioned Fear for Drug Development.Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response.
P2860
Q27006437-2E58D81F-097C-4B5A-918D-E4E1C65751E0Q28389310-9031A76D-6EA6-4852-9CDA-7E5757D0E6E9Q30375098-CD2CAE8F-182D-4024-B8C5-DFA4D906250AQ30410039-872CFEC7-F7E7-4341-8BDE-B94728A5578BQ30410131-272600C1-091D-46E3-9292-255DF1EEE485Q33708292-A4BDCA27-5185-4DA8-A0AC-DA6D81DE2400Q34338841-033C9CA9-807C-4B7F-834C-0DDD873EF885Q34357046-617E9454-A2C8-4E84-87BA-4F6BE99748D3Q34410902-5B4BC0F3-7185-4302-8D03-DB5C86A1ABF1Q34926000-6E06A85A-4E0B-4FF4-9432-0A3CB5E6A9F5Q35098882-E62826C7-4169-44AA-8BE4-B4ED62AEB0FEQ35551573-2AB4C692-C309-4934-8CFA-98472509C5A3Q36328780-4F6C4655-BDAD-45F1-BC8F-8438BAF8DECAQ36935148-A888C773-7292-4325-91BE-384D797E47ADQ37309767-F363D1BE-E492-45EF-9AE7-29CA2D0350E8Q38674558-4A9444C8-86A1-4293-BF77-200E6E3FEEEEQ38852116-CD4D144B-9116-4AE8-93FB-B91B77B5D19EQ46521486-61AA88F0-CCD4-4838-BD50-666F5FE7FAC0
P2860
Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effect of D-cycloserine and va ...... a randomized controlled trial.
@en
Effect of D-cycloserine and va ...... a randomized controlled trial.
@nl
type
label
Effect of D-cycloserine and va ...... a randomized controlled trial.
@en
Effect of D-cycloserine and va ...... a randomized controlled trial.
@nl
prefLabel
Effect of D-cycloserine and va ...... a randomized controlled trial.
@en
Effect of D-cycloserine and va ...... a randomized controlled trial.
@nl
P2093
P2860
P1433
P1476
Effect of D-cycloserine and va ...... a randomized controlled trial.
@en
P2093
Kenichi Kuriyama
Takahiro Soshi
Takeshi Fujii
Yoshiharu Kim
P2860
P2888
P304
P356
10.1007/S00213-011-2353-X
P577
2011-05-19T00:00:00Z